A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer; does trastuzumab interfere With the outcome?

Joudi, Maryam, Moradi Binabaj, Maryam, Porouhan, Pejman, PeyroShabany, Babak, Tabasi, Mohsen, Fazilat-Panah, Danial, Khajeh, Mahtab, Mehrabian, Arezoo, Dehghani, Mansoureh, Welsh, James S, Keykhosravi, Batol, Akbari Yazdi, Azam, Ariamanesh, Mona, Ghasemi, Ahmad, Ferns, Gordon and Javadinia, Seyed Alireza (2022) A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer; does trastuzumab interfere With the outcome? Frontiers in Endocrinology, 13. pp. 1-7. ISSN 1664-2392

[img] PDF - Published Version
Available under License Creative Commons Attribution.

Download (310kB)

Abstract

Aim
To determine the efficacy and safety of inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer.

Methods
In this multi- institutional cohort study, a total of 160 breast cancer patients (mean age of 50.01 ± 11.5 years old) were assessed for the SARS-CoV-2 Anti-Spike IgG and SARS-CoV2 Anti RBD IgG by ELISA after two doses of 0.5 mL inactivated, COVID-19 vaccine (BBIBP-CorV). All patients were followed up for three months for clinical COVID-19 infection based on either PCR results or imaging findings. Common Terminology Criteria for Adverse Events were used to assess the side effects.

Results
The presence of SARS-CoV-2 anti-spike IgG, SARS-CoV2 anti-RBD IgG, or either of these antibodies was 85.7%, 87.4%, and 93.3%. The prevalence of COVID-19 infection after vaccination was 0.7%, 0% and 0% for the first, second and third months of the follow-up period. The most common local and systemic side-effects were injection site pain and fever which were presented in 22.3% and 24.3% of patients, respectively.

Discussion
The inactivated SARS-CoV-2 vaccine (BBIBP-CorV) is a tolerable and effective method to prevent COVID-19.

Item Type: Article
Keywords: COVID-19 vaccine, Iran, SARS-CoV2, breast cancer, cancer, inactivated SARS-CoV-2 vaccine;malignancy;seroconversion;Adult;Antibodies, Viral;Breast Neoplasms;COVID-19;COVID-19 Vaccines;Cohort Studies;Female;Humans;Middle Aged;RNA, Viral;SARS-CoV-2;Trastuzumab
Schools and Departments: Brighton and Sussex Medical School > Division of Medical Education
SWORD Depositor: Mx Elements Account
Depositing User: Mx Elements Account
Date Deposited: 28 Jul 2022 13:12
Last Modified: 28 Jul 2022 13:12
URI: http://sro.sussex.ac.uk/id/eprint/107158

View download statistics for this item

📧 Request an update